Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Indications Cancer”

30 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 30 results

Not applicableWithdrawnNCT03161613
What this trial is testing

Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico

Who this might be right for
Multiple Indications Cancer
Bristol-Myers Squibb
Not applicableNot Yet RecruitingNCT07295171
What this trial is testing

HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG

Who this might be right for
Multiple CancersMultiple Indications CancerFeasibility Studies
British Columbia Cancer Agency 27
Early research (Phase 1)Study completedNCT01772004
What this trial is testing

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Who this might be right for
Solid Tumors
EMD Serono Research & Development Institute, Inc. 1,756
Not applicableWithdrawnNCT03983486
What this trial is testing

Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Centre Hospitalier Universitaire, Amiens
Testing effectiveness (Phase 2)Study completedNCT02297139
What this trial is testing

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Who this might be right for
Multiple Indications Cancer
Bristol-Myers Squibb 17
Not applicableStudy completedNCT01294722
What this trial is testing

Determine the Number of Participants With Rheumatoid Arthritis (RA) Who Meet the Requirements for Treatment With Anti-Tumor Necrosis Factor α (TNFα) in a General Hospital Setting in Korea

Who this might be right for
Rheumatoid Arthritis
Janssen Korea, Ltd., Korea 1,700
Testing effectiveness (Phase 2)UnknownNCT03018405
What this trial is testing

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

Who this might be right for
Acute Myeloid Leukemia/Myelodysplastic SyndromeMultiple Myeloma (MM)
Celyad Oncology SA 146
Testing effectiveness (Phase 2)Ended earlyNCT02465528
What this trial is testing

Ceritinib Rare Indications Study in ALK+ Tumors

Who this might be right for
Tumors With Aberrations in ALKAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumor+1 more
Novartis Pharmaceuticals 22
Early research (Phase 1)Study completedNCT03523390
What this trial is testing

Phase I/Ib Multiple Ascending Dose Study in China

Who this might be right for
Metastatic Solid Tumors
Merck KGaA, Darmstadt, Germany 24
Testing effectiveness (Phase 2)Looking for participantsNCT04817956
What this trial is testing

Improving Public Cancer Care by Implementing Precision Medicine in Norway

Who this might be right for
Cancer Metastatic
Oslo University Hospital 3,000
Not applicableLooking for participantsNCT06635954
What this trial is testing

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

Who this might be right for
CancerImmunotherapyPD-1+2 more
Oxford Biodynamics Inc. 2,000
Large-scale testing (Phase 3)Looking for participantsNCT04513639
What this trial is testing

The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

Who this might be right for
Multiple Myeloma
Oslo University Hospital 176
Large-scale testing (Phase 3)Study completedNCT00522951
What this trial is testing

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Who this might be right for
Brain Metastases
Bayer 165
Testing effectiveness (Phase 2)Study completedNCT04704154
What this trial is testing

A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Who this might be right for
Solid Tumors
Bayer 175
Early research (Phase 1)Study completedNCT02517398
What this trial is testing

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

Who this might be right for
Solid Tumors
EMD Serono Research & Development Institute, Inc. 600
Not applicableUnknownNCT02281188
What this trial is testing

Registry for Treatment of Upper Urinary Tract Tumours

Who this might be right for
Upper Urinary Tract Tumours
Clinical Research Office of the Endourological Society 2,451
Testing effectiveness (Phase 2)Looking for participantsNCT07280377
What this trial is testing

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Who this might be right for
Anal Cancer MetastaticSquamous Cell Carcinoma of the Anus Stage UnspecifiedPancreatic Cancer Metastatic+1 more
Oncolytics Biotech 122
Large-scale testing (Phase 3)Looking for participantsNCT05768178
What this trial is testing

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Who this might be right for
Haematological MalignancyMelanomaThyroid Cancer, Papillary+9 more
Cancer Research UK 30
Testing effectiveness (Phase 2)WithdrawnNCT01479582
What this trial is testing

Providing Access to Cord Blood Units for Transplants

Who this might be right for
Chronic Myelogous Leukemia/Other LeukemiaAcute LeukemiasMDS/MPS+2 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT02699515
What this trial is testing

MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors

Who this might be right for
Solid Tumors
Merck KGaA, Darmstadt, Germany 114
Load More Results